Exchange: NASDAQ·Updated 07:54 PM EDT

VERX News

News
all
press releases
If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals has a marketread more...
Benzinga
If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals has a marketread more...
Benzinga
More News
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Key PointsAmgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow...
Nasdaq News: Markets
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Key PointsAxsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders...
Nasdaq News: Markets
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
Key PointsVertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance...
Nasdaq News: Markets
Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Vertex and Okta, while cutting targets for McDonald's, AutoZone, Vaxcyte and Camping World.read more...
Benzinga
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsCRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY...
Nasdaq News: Markets
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.read more...
Benzinga
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAmgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally...
Nasdaq News: Markets
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
Key PointsVertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas...
Nasdaq News: Markets
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
Key PointsVertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area...
Nasdaq News: Markets

Advertisement|Remove ads.